CNS pipeline · person
Gillian Cannon, PhD
Director of Xenon Pharmaceuticals since August 2023, with more than 30 years in the pharmaceutical industry in leadership roles at Merck, UCB and Otsuka, and most recently Head of Commercial Innovation at Roivant Sciences. She holds a B.Sc. in Biochemistry from the University of Edinburgh and a Ph.D. in Health Administration from Temple University.
- 1 company
Current roles
- Xenon Pharmaceuticals Inc.Director · Board
Appears with
People sharing a company with Gillian.
- Andrea DiFabio · Xenon Pharmaceuticals Inc.
- Christopher Kenney · Xenon Pharmaceuticals Inc.
- Darren Cline · Xenon Pharmaceuticals Inc.
- Dawn Svoronos · Xenon Pharmaceuticals Inc.
- Elizabeth Garofalo · Xenon Pharmaceuticals Inc.
- Gary Patou · Xenon Pharmaceuticals Inc.
- Ian Mortimer · Xenon Pharmaceuticals Inc.
- James Empfield · Xenon Pharmaceuticals Inc.
- Justin Gover · Xenon Pharmaceuticals Inc.
- Matthew D. Ronsheim · Xenon Pharmaceuticals Inc.
- Michael Hayden · Xenon Pharmaceuticals Inc.
- Patrick Machado · Xenon Pharmaceuticals Inc.
- Robin Sherrington · Xenon Pharmaceuticals Inc.
- Shelley McCloskey · Xenon Pharmaceuticals Inc.
- Steven Gannon · Xenon Pharmaceuticals Inc.
- Tucker Kelly · Xenon Pharmaceuticals Inc.
People and affiliation data assembled from public company disclosures, SEC filings, and conference materials — every record source-cited under psychiatrist-authored guardrails.